News
BrainCells Inc. Announces the Successful Completion of the Single Ascending Dose Study With BCI-838 and the Initiation of the Multiple Ascending Dose Study
Bio-Medicine
February 29, 2012
Unlikely treatment identified by Braincells neurogenesis platform improved clinical outcomes in patients suffering from depression
Download the PDF
July 27, 2009
BrainCells expands Series B financing to $50 million
Download the PDF
April 17, 2008
BrainCells Inc. initiates Phase 2 clinical trial with BCI-540 for depression with anxiety
Download the PDF
April 17, 2008
BrainCells, Taisho Pharmaceutical, sign licensing agreement for novel CNS program
Download the PDF
September 27, 2007
BrainCells
San Diego, CA
BrainCells (BCI) is a leading-edge neurogenesis-based drug discovery and development company targeting novel therapies for depression, mood disorders and other CNS diseases. The company is developing a neurogenesis platform for profiling and selecting drug candidates. BCI believes that the platform represents a major improvement in the predictive power of pre-clinical models for CNS disorders and will facilitate a paradigm shift in the way CNS drugs are discovered.